PDS Biotech reports 29.5 months of mOS in low PD-L1 expression patients with head and ...

Retrieved on: 2025-09-18 13:07:08

Tags for this article:

Click the tags to see associated articles and topics

PDS Biotech reports 29.5 months of mOS in low PD-L1 expression patients with head and .... View article details on hiswai:

Excerpt

... immune response of ... This study is part of PDS Biotechnology's broader effort to transform how the immune system targets and kills cancers.

Article found on: www.ainvest.com